The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Surgical resection in locally advanced pancreatic cancer
Michele Milella, MD, University of Verona, Verona, Italy, discuss resection in the locally advanced pancreatic cancer (LAPC) population, highlighting the low resectability rate in this cohort even with neoadjuvant treatment. In the TRIPP-FFX study (NCT05466799) evaluating the feasibility and tolerability of induction FOLFIRINOX chemotherapy with targeted intratumoral placement of phosphorus-32 (P-32) microparticles in unresectable LAPC, no difference was observed in the number of patients that underwent subsequent surgical resection between those that received the combination and those that received FOLFIRINOX alone. However, of those that received P-32, 60% had resection with R0 margins, whereas only 20% of those that received FOLFIRINOX alone had the same margins. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
